328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407

Y Cheng,L Zhang,J Hu,D Wang,C.P Hu,J Zhou,L Wu,L Cao,J Liu,H Zhang,H Sun,Z Wang,H Gao,Y Sun,X Hu,E Jensen,P.O Schwarzenberger,L Paz-Ares

doi:10.1016/j.annonc.2022.10.367

328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407

Y Cheng, L Zhang + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.367

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Jilin Province Tumor Hospital, Peking Union Medical College Hospital, Fudan University, Chongqing Cancer Hospital, Xiangya Hospital Central South University, First Affiliated Hospital Zhejiang University, Hunan Cancer Hospital, First Affiliated Hospital of Dalian Medical University, Tang Du Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Peking University Cancer Hospital, Academy of Military Medical Sciences, Hospital Universitario 12 De Octubre

#Metastatic Squamous Non-small Cell Lung #Squamous Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

First-line pembrolizumab (pembro) + paclitaxel and carboplatin (chemo) improved outcomes vs placebo (pbo) + chemo in Chinese patients (pts) with metastatic squamous NSCLC enrolled in the KEYNOTE-407 global and China extension studies, consistent with the global study population. We report long-term outcomes in Chinese pts from these studies.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.